U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Endometrial Undifferentiated Carcinoma

MedGen UID:
1718245
•Concept ID:
C5237069
•
Neoplastic Process

Definition

Endometrial undifferentiated carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Endometrial Undifferentiated Carcinoma

Professional guidelines

PubMed

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z, Hayato S, Tamai T, Makker V
Expert Rev Anticancer Ther 2022 Apr;22(4):383-400. Epub 2022 Apr 7 doi: 10.1080/14737140.2022.2039123. PMID: 35260027Free PMC Article
GnRH antagonists in the treatment of gynecological and breast cancers.
Emons G, Gründker C, Günthert AR, Westphalen S, Kavanagh J, Verschraegen C
Endocr Relat Cancer 2003 Jun;10(2):291-9. doi: 10.1677/erc.0.0100291. PMID: 12790790
Ifosfamide in the management of gynecologic cancers.
Thigpen T, Lambuth BW, Vance RB
Semin Oncol 1990 Apr;17(2 Suppl 4):11-8. PMID: 2185545

Recent clinical studies

Etiology

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
A Risk-scoring Model for Predicting Post-recurrence Survival in Patients With Endometrial Carcinoma.
Kolehmainen A, Pasanen A, Koivisto-Korander R, Bützow R, Loukovaara M
Clin Oncol (R Coll Radiol) 2023 Jul;35(7):472-477. Epub 2023 May 6 doi: 10.1016/j.clon.2023.05.001. PMID: 37173220
SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.
Tessier-Cloutier B, Coatham M, Carey M, Nelson GS, Hamilton S, Lum A, Soslow RA, Stewart CJ, Postovit LM, Köbel M, Lee CH
J Pathol Clin Res 2021 Mar;7(2):144-153. Epub 2020 Oct 30 doi: 10.1002/cjp2.188. PMID: 33125840Free PMC Article
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.
Miyamoto M, Takano M, Kuwahara M, Soyama H, Kato K, Matuura H, Sakamoto T, Takasaki K, Aoyama T, Yoshikawa T, Furuya K
Cancer Chemother Pharmacol 2018 Jan;81(1):111-117. Epub 2017 Nov 9 doi: 10.1007/s00280-017-3454-y. PMID: 29124328
Circadian chemotherapy for gynecological and genitourinary cancers.
Kobayashi M, Wood PA, Hrushesky WJ
Chronobiol Int 2002 Jan;19(1):237-51. doi: 10.1081/cbi-120002600. PMID: 11962679

Diagnosis

A Risk-scoring Model for Predicting Post-recurrence Survival in Patients With Endometrial Carcinoma.
Kolehmainen A, Pasanen A, Koivisto-Korander R, Bützow R, Loukovaara M
Clin Oncol (R Coll Radiol) 2023 Jul;35(7):472-477. Epub 2023 May 6 doi: 10.1016/j.clon.2023.05.001. PMID: 37173220
SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.
Tessier-Cloutier B, Coatham M, Carey M, Nelson GS, Hamilton S, Lum A, Soslow RA, Stewart CJ, Postovit LM, Köbel M, Lee CH
J Pathol Clin Res 2021 Mar;7(2):144-153. Epub 2020 Oct 30 doi: 10.1002/cjp2.188. PMID: 33125840Free PMC Article
Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.
Abdul Munem A, Al-Bahrani B, Mehdi I, Kamona A, Nadas AM
J Pak Med Assoc 2012 May;62(5):505-7. PMID: 22755322
Chylous ascites following treatment for gynecologic malignancies.
Manolitsas TP, Abdessalam S, Fowler JM
Gynecol Oncol 2002 Sep;86(3):370-4. doi: 10.1006/gyno.2002.6754. PMID: 12217764
Endometrial neoplasia: prognostic significance of ploidy status.
Evans MP, Podratz KC
Clin Obstet Gynecol 1996 Sep;39(3):696-706. doi: 10.1097/00003081-199609000-00017. PMID: 8862893

Therapy

A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.
Atkins SLP, Greer YE, Jenkins S, Gatti-Mays ME, Houston N, Lee S, Lee MJ, Rastogi S, Sato N, Burks C, Annunziata CM, Lee JM, Nagashima K, Trepel JB, Lipkowitz S, Zimmer AS
Oncologist 2023 Oct 3;28(10):919-e972. doi: 10.1093/oncolo/oyad164. PMID: 37279797Free PMC Article
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z, Hayato S, Tamai T, Makker V
Expert Rev Anticancer Ther 2022 Apr;22(4):383-400. Epub 2022 Apr 7 doi: 10.1080/14737140.2022.2039123. PMID: 35260027Free PMC Article
Loratadine for Paclitaxel-Induced Myalgias and Arthralgias.
Smith C, Hendrickson AW, Grudem M, Klampe C, Deering E, Jatoi A
Am J Hosp Palliat Care 2020 Mar;37(3):235-238. Epub 2019 Jul 17 doi: 10.1177/1049909119864083. PMID: 31315424
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M, Obata T, Daikoku T, Fujiwara H
Int J Mol Sci 2019 Nov 4;20(21) doi: 10.3390/ijms20215482. PMID: 31689961Free PMC Article
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.
Miyamoto M, Takano M, Kuwahara M, Soyama H, Kato K, Matuura H, Sakamoto T, Takasaki K, Aoyama T, Yoshikawa T, Furuya K
Cancer Chemother Pharmacol 2018 Jan;81(1):111-117. Epub 2017 Nov 9 doi: 10.1007/s00280-017-3454-y. PMID: 29124328

Prognosis

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
A Risk-scoring Model for Predicting Post-recurrence Survival in Patients With Endometrial Carcinoma.
Kolehmainen A, Pasanen A, Koivisto-Korander R, Bützow R, Loukovaara M
Clin Oncol (R Coll Radiol) 2023 Jul;35(7):472-477. Epub 2023 May 6 doi: 10.1016/j.clon.2023.05.001. PMID: 37173220
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M
Gynecol Oncol 2023 May;172:82-91. Epub 2023 Mar 29 doi: 10.1016/j.ygyno.2023.03.013. PMID: 37001446
Immunosuppressive tumor microenvironment in uterine serous carcinoma via CCL7 signal with myeloid-derived suppressor cells.
Mise Y, Hamanishi J, Daikoku T, Takamatsu S, Miyamoto T, Taki M, Yamanoi K, Yamaguchi K, Ukita M, Horikawa N, Abiko K, Murakami R, Furutake Y, Hosoe Y, Terakawa J, Kagabu M, Sugai T, Osakabe M, Fujiwara H, Matsumura N, Mandai M, Baba T
Carcinogenesis 2022 Aug 30;43(7):647-658. doi: 10.1093/carcin/bgac032. PMID: 35353883
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M, Obata T, Daikoku T, Fujiwara H
Int J Mol Sci 2019 Nov 4;20(21) doi: 10.3390/ijms20215482. PMID: 31689961Free PMC Article

Clinical prediction guides

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
A Risk-scoring Model for Predicting Post-recurrence Survival in Patients With Endometrial Carcinoma.
Kolehmainen A, Pasanen A, Koivisto-Korander R, Bützow R, Loukovaara M
Clin Oncol (R Coll Radiol) 2023 Jul;35(7):472-477. Epub 2023 May 6 doi: 10.1016/j.clon.2023.05.001. PMID: 37173220
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M
Gynecol Oncol 2023 May;172:82-91. Epub 2023 Mar 29 doi: 10.1016/j.ygyno.2023.03.013. PMID: 37001446
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M, Obata T, Daikoku T, Fujiwara H
Int J Mol Sci 2019 Nov 4;20(21) doi: 10.3390/ijms20215482. PMID: 31689961Free PMC Article
Endometrial neoplasia: prognostic significance of ploidy status.
Evans MP, Podratz KC
Clin Obstet Gynecol 1996 Sep;39(3):696-706. doi: 10.1097/00003081-199609000-00017. PMID: 8862893

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...